Last updated: 2026-09-07 21:59:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Erasca, Inc. (ERAS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $16,20, with a market capitalization of $5,66B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,53 to $24,28. This page covers its latest market performance, valuation, price trends and company information.
$5,66B | |
$16,04 | |
$24,47 | |
$1,01 | |
$16,26 | |
1,55M | |
4,56M | |
-- | |
$24,28 | |
$1,53 | |
-- | |
-- |
Erasca, Inc. (ERAS) last closed at $16,26 as of 2026-09-04 23:46:00, unchanged from the previous close of $16,26.
During the latest regular trading session, ERAS traded between $1,01 and $24,47, with a volume of 1,55M shares. The closing price was near the middle and near the middle of its 52-week range.
Over the past seven days, Erasca, Inc. (ERAS) moved from $19,49 to $16,20, representing a decline of 16,88% ($3,29).
The stock traded between $15,77 and $20,40 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 4,20 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 64,5%
ERAS is currently trading at $16,20, placing it 64,5% of the way from its 52-week low of $1,53 to its 52-week high of $24,28. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 103 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Erasca, Inc. (ERAS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.